Evidence map›Paper›PMID 42553364›Full record

ArticleFrontiers in immunology2026

Targeting the AHR-IDO1-kynurenine pathway in TREM2

Fei Le, Xianming Huang, Youfang Jiang, Saiping Lv, Yaoyao Chen

Abstract read
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Fei LeDepartment of Head and Neck Tumor Surgery, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, China.
Xianming HuangDepartment of Medical Pathology, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, China.
Youfang JiangDepartment of Head and Neck Tumor Surgery, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, China.
Saiping LvDepartment of Medical Laboratory, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, Jiangxi, China.
Yaoyao ChenMedical College of Nanchang University, Nanchang, Jiangxi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Advances in single-cell technologies have provided detailed insight into cellular heterogeneity within tumor microenvironments. However, the regulatory mechanisms driving macrophage-mediated immune suppression in thyroid cancer remain incompletely understood. Methods: We applied integrated single-cell multi-omics approaches to tumor samples from patients and murine thyroid cancer models, including single-cell RNA sequencing, single-cell ATAC sequencing, mass cytometry, spatial/histological validation, and in vitro and in vivo functional assays. Results: We identified a prominent enrichment of TREM2 Discussion: These findings reveal a TREM2

Indexed as

Indoleamine-Pyrrole 2,3,-DioxygenaseKynurenineMacrophagesMembrane GlycoproteinsReceptors, Aryl HydrocarbonReceptors, ImmunologicThyroid NeoplasmsTumor-Associated MacrophagesAnimalsCell Line, TumorFemaleHumansMiceSignal TransductionTumor MicroenvironmentIDO1 protein, humanIndoleamine-Pyrrole 2,3,-DioxygenaseKynurenineMembrane GlycoproteinsReceptors, Aryl HydrocarbonReceptors, Immunologicaryl hydrocarbon receptor-indoleamine 2,3-dioxygenase 1 pathwayimmune evasionkynurenine metabolismsingle-cell omicsthyroid cancerTREM2+ macrophages

Identifiers

PMID42553364
PMCPMC13433865

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.